Mikhail Blagosklonny Develops Oncotarget for Cancer Research and Treatment

Cancer remains the number one life-threatening disease in the world. With it comes an emotional, financial and physical challenge for both the infected and affected. It takes more than just a family to fight the disease. Currently, approximately 6.7 million people lose their lives to cancer every year. That is why scientists and physicians have heavily invested in cancer research centers and journals with the objective of finding treatment. Cancer Treatment involves growth regulation in the body cells. A good example of such journals is the Oncotarget.

Oncotarget

Oncotarget is a weekly medical journal on research covering all scopes of oncology. After its establishment in 2010, Impact Journals took the role of publishing it. The chief editors of the journal are prominent scientists; Mikhail Blagosklonny, an oncologist and lead researcher at Roswell Research Center for Cancer and Andrei V. Gudkov. The journal plays a vital role in the dissemination of cancer-related information to the community. With its weekly publications, most people can be reached.

Research

The quest to find treatment for cancer is massively gaining support from private and public sectors. Individuals are adopting modern research methods and ideas to treat diseases. With Oncotarget being a top scientific journal, most physicians embark on it for research. Families and patients refer to Oncotarget for educative reasons. Oncotarget has made remarkable gains discernible by educative articles on the symptoms and treatment of cancer.

E-Cigarettes

Recently, an innovative research by Oncotarget showed that e-cigarettes have adverse effects on smoker’s gums. Additionally, Oncotarget has published new research on cervical cancer and drugs being the causative agents for weight loss in cancer patients. Oncotarget further explains the possibilities of a strong modern element that can be utilized in the treatment of cancer. The new researchers play an essential role in tackling cancer. They also offer an innovative platform for the research and treatment of e-cigarette. Most researchers illuminate the possibility of misconception in conformism. Oncotarget is also available on Dove Press.

Mikhail Blagosklonny

Mikhail Blagosklonny serves as the chief editor of Oncotarget, a multidisciplinary conventional journal freely accessible. Under his leadership, Oncotarget publishes articles online with the aim of educating the community on cancer awareness, research, and treatment. Each article is readily available for printing upon demand. Follow Oncotarget journal on Twitter.